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Results: Taxotere could inhibit the proliferation of A549 cell by a 
time and dose-dependent manner and the combination with Celecoxib 
(12.5µmol/l, 25µmol/l) could improve the inhibition. After 48h of incu-
bation with Taxotere, the highest inhibitory rate of the cell is 65% and 
the lowest inhibitory rate is 10%. High-dose celecoxib (>50µmol/l) can 
suppress COX-2 gene expression, while positive response was found 
in low-dose celecoxib(12.5µmol/l,25µmol/l) and the combination. 
Celecoxib can increase the percentage of cell in G0/G1 and decrease 
that in S and G2/M. The apoptosis rate of cell increased after Celecoxib 
combined with Taxotere. 
Conclusion: Taxotere could inhibit effectively the growth of A549 cell 
lines in vitro and the combination with Celecoxib could improve the 
inhibition through induceing apopotosis and inﬂuencing the distribu-
tion of cell cycle, but had no signiﬁcant inﬂuence in the expression of 
COX-2 protein.
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Background: Pemetrexed is an effective salvage agent in NSCLC 
patients failing previous chemotherapy. Our aim was to evaluate the 
efﬁcacy of pemetrexed in Chinese NSCLC patients who had failed 
previous platinum-based chemotherapy and had been salvaged with 
tyrosine-kinase inhibitor (TKI) treatment or not. 
Methods: Treatment consisted of pemetrexed 500 mg/m2 intravenous 
infusion on day 1 of every 3 weeks. Standard premedications, including 
vitamin B12, folic acid, and dexamethasone were given.
Results: Between June 2005 and November 2006, 44 patients (pts) 
were enrolled and completed the study. All had been treated with 
platinum-based chemotherapy. Thirty patients had been treated with 
TKI after they failed platinum-based chemotherapy. The present treat-
ment was second-line treatment in 10 pts, and third-line or higher in 
34 pts. Mean age was 62. Median cycles received was 4, and objective 
response rates was 18.2% (8 pts had PR). Treatment-related toxicities 
were mild and few. Grade 3 or 4 haematological toxicities included 
neutropenia in 18.2%, thrombocytopenia in 6.8%, and anemia in 4.5 
pts. Non-haematological toxicities were all less than grade 3. Median 
time to disease progression was 4.4 months and median survival was 
9.1 months. Those received present treatment as second line treat-
ment had a better response than as third line or later treatment (40% 
vs. 11.8%, p=0.043). Previous treatment with TKI or not did not affect 
patient’s response to present treatment (p=0.782) 
Conclusions: This study demonstrated that pemetrexed salvage chemo-
therapy in NSCLC patients who have failed previous platinum-based 
chemotherapy produces a relatively lower toxicity proﬁle, and a better 
compliance and response rate than conventional salvage chemotherapy. 
Use of pemetrexed as second line agent will have better response rate 
than as third line or later treatment. 
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Background: Our aim here was to determine whether or not add-
ing cisplatin into vinorelbine treatment is an appropriate regimen for 
chemo-naïve NSCLC in patients aged 70 or older.
Methods: After stratiﬁcation by performance status, patients were 
randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) 
treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intrave-
nous infusion on days 1 and 8 of every 3 weeks (V arm), or vinorelbine 
22.5 mg/m2 intravenous infusion on days 1 and 8, and cisplatin 60 
mg/m2 intravenous infusion on day 1 of every 3 weeks (VP arm). From 
May 2005 to December 2006, 68 patients were enrolled. Sixty-three 
patients went off-study before end of February 2007. Present analysis 
was based on these 63 patients.
Results: There were 29 patients received V treatment and 34 patients 
received VP treatment. There was no statistical signiﬁcant difference in 
clinical characteristics. In all, 104 cycles of V (median, 4 cycles per pa-
tient) and 137 cycles of VP (median, 4 cycles per patient) were given. 
Objective response rates were 17.2% in V and 32.4% in VP (p=0.175). 
Control rates were 51.7% in V and 82.4% in VP (p=0.009). Myelo-
suppression was more common and severe in VP arm. Any grade of 
anemia and neutropenia were signiﬁcantly higher in VP arm (p=0.002 
and 0.018, respectively). Two patients in VP arm suffered from febrile 
neutropenia and one patient died in spite of G-CSF and antibiotic 
treatment. There was only one patient in V arm who had uneventful 
febrile neutropenia. Non-haematological toxicities was mild and all less 
than grade 3, except one patient in VP arm who suffered from grade 3 
renal function impairment and one patient in V arm who had grade 3 
phlebitis. Fatigue sensation was more common and severe in VP arm 
(p=0.031). Median time to disease progression was 2.7 months in V 
arm and 5.2 months in VP arm (p=0.0125). One-year survival rate was 
49.8% in V arm and 45.4% in VP arm.
Conclusions: Adding cisplatin into vinorelbine treatment is feasible in 
elderly patients, and has better disease control rate and longer me-
dian time to disease progression. However, vinorelbine plus cisplatin 
treatment was more toxic than vinorelbine treatment alone in elderly 
patients.
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The effects of NSCLC neoadjuvant therapy on the serum and 
tumor levels of growth factors, apoptosis and invasiveness markers
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Our aim was to evaluate the effect of neoadjuvant therapy and subse-
quent surgical treatment of non-small cell lung cancer (NSCLC) on 
serum markers of tumor growth and expansion: VEGF, TGF-β, bFGF, 
TIMP-1 and apoptosis marker CD95L assessed by Elisa. 24 NSCLC 
patients were evaluated: 12 in stage IIIA. 9-IIB,1-IIA, 1-IB, 1-IA. 
